請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76416
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟 | |
dc.contributor.author | Ching-Yen Su | en |
dc.contributor.author | 蘇靖晏 | zh_TW |
dc.date.accessioned | 2021-07-09T15:52:02Z | - |
dc.date.available | 2023-10-05 | |
dc.date.copyright | 2018-10-05 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-03 | |
dc.identifier.citation | 1. Taiwan Guideline for the Management of Gout and Hyperuricemia Updated 2013. Taiwan Rheumatalogy Association.
2. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446. 3. Allopurinol. Drugs@FDA: FDA Approved Drug Products. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016084. Accessed Mar. 29, 2018. 4. Uloric (febuxostat) Tablets. Drug Approval Package. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/021856s000TOC.cfm. Accessed Mar. 29, 2018. 5. Adenuric (febuxostat). Human medicines. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000777/human_med_000627.jsp&mid=WC0b01ac058001d124. Accessed Mar. 29, 2018. 6. Review Reports: Drugs. Pharmaceuticals and Medical Devices Agency. http://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html#select6. Accessed Mar. 29, 2018. 7. 西藥、醫療器材、化粧品許可證查詢. 衛生福利部食品藥物管理署. https://www.fda.gov.tw/MLMS/H0001.aspx. Accessed Mar. 29, 2018. 8. 健保用藥品項網路查詢服務. 衛生福利部中央健康保險署. https://www.nhi.gov.tw/Query/query1.aspx?menu=20&menu_id=712&WD_ID=831. Accessed Mar. 29, 2018. 9. Micromedex® 2.0, (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com/ (cited: 3/28/2018). 10. Taiwan Guideline for the Management of Gout and Hyperuricemia Updated 2016. Taiwan Rheumatalogy Association. 11. Becker MA, Schumacher HR, Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461. 12. Becker MA, Schumacher HR, Jr., Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916-923. 13. Schumacher HR, Jr., Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. 14. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-1282. 15. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. 16. Schumacher HR, Jr., Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188-194. 17. Gandhi PK, Gentry WM, Bottorff MB. Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database. Semin Arthritis Rheum. 2013;42(6):562-566. 18. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200-1210. 19. Uloric (febuxostat): Drug Safety Communication - FDA to Evaluate Increased Risk of Heart-related Death. U.S. Food and Drug Administration. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm585281.htm. Accessed Apr. 6, 2018. 20. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3(8):443-449. 21. Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24(6):811-827. 22. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol. 2001;28(7):1640-1646. 23. 2005-2008 國人尿酸及痛風之狀況. Nutrition And Health Survey in Taiwan. http://nahsit-form.ibms.sinica.edu.tw/node/20. Accessed May 12, 2018. 24. Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr. 2011;20(2):301-308. 25. Chen JH, Yeh WT, Chuang SY, Wu YY, Pan WH. Gender-specific risk factors for incident gout: a prospective cohort study. Clin Rheumatol. 2012;31(2):239-245. 26. Kuo CF, Grainge MJ, See LC, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17:13. 27. Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(8):1470-1476. 28. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900. 29. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557-2568. 30. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2095-2128. 31. Borghi C, Verardi FM, Pareo I, Bentivenga C, Cicero AF. Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther. 2014;12(10):1219-1225. 32. Brand FN MD, Kannel WB, Stokes J 3rd, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985;121(1):11-8. 33. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-110. 34. Perlstein TS, Gumieniak O, Hopkins PN, et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int. 2004;66(4):1465-1470. 35. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Journal of the American College of Cardiology. 2014;63(25):2935-2959. 36. Grassi D, Ferri L, Desideri G, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432-2438. 37. Ndrepepa G, Braun S, Haase HU, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012;109(9):1260-1265. 38. Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15-24. 39. Dutta A, Henley W, Pilling LC, Wallace RB, Melzer D. Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc. 2013;61(3):319-326. 40. Savarese G, Ferri C, Trimarco B, et al. Changes in serum uric acid levels and cardiovascular events: a meta-analysis. Nutr Metab Cardiovasc Dis. 2013;23(8):707-714. 41. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. 42. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993;14(6):615-631. 43. Odden MC, Amadu AR, Smit E, Lo L, Peralta CA. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis. 2014;64(4):550-557. 44. Kang E, Hwang SS, Kim DK, et al. Sex-specific Relationship of Serum Uric Acid with All-cause Mortality in Adults with Normal Kidney Function: An Observational Study. J Rheumatol. 2017;44(3):380-387. 45. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36(6):1072-1078. 46. Hsu SP. Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrology Dialysis Transplantation. 2004;19(2):457-462. 47. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. 48. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-4139. 49. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643-665. 50. Yu KH, Chen DY, Chen JH, et al. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21(4):772-787. 51. Cheng CL, Chao PH, Hsu JC, Weng MM, On AW, Yang YH. Utilization patterns of antihyperuricemic agents following safety announcement on allopurinol and benzbromarone by Taiwan Food and Drug Administration. Pharmacoepidemiol Drug Saf. 2014;23(3):309-313. 52. Robbins N, Koch SE, Tranter M, Rubinstein J. The history and future of probenecid. Cardiovasc Toxicol. 2012;12(1):1-9. 53. Frampton JE. Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. Drugs. 2015;75(4):427-438. 54. Chinchilla SP, Urionaguena I, Perez-Ruiz F. Febuxostat for the chronic management of hyperuricemia in patients with gout. Expert Rev Clin Pharmacol. 2016;9(5):665-673. 55. 「藥品給付規定」修正. Febuxostat(如Feburic)之給付規定(自101年4月1日起生效). 衛生福利部中央健康保險署. http://www.tsim.org.tw/helth/hel245_m462.html. Accessed Mar. 29, 2018. 56. 「藥品給付規定」修正. Febuxostat(如Feburic)之給付規定(自103年3月1日起生效). 衛生福利部中央健康保險署. http://www.nhi.gov.tw/Resource/bulletin/5016_%E4%BF%AE%E6%AD%A3%E8%A6%8F%E5%AE%9A.pdf. Accessed Mar. 29, 2018. 57. 「藥品給付規定」修正. Febuxostat(如Feburic)之給付規定(自105年8月1日起生效). 衛生福利部中央健康保險署. https://www.nhi.gov.tw/Resource/bulletin/6455_1050035921-2.pdf. Accessed Mar. 29, 2018. 58. Product Information: allopurinol oral tablets, allopurinol oral tablets. Northstar Rx LLC (per DailyMed), Memphis, TN, 2015. 59. Product Information: ULORIC(R) oral tablets, febuxostat oral tablets. Takeda Pharmaceuticals America, Inc. (per DailyMed), Deerfield, IL, 2013. 60. Zhang J, Dierckx R, Mohee K, Clark AL, Cleland JG. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis. ESC Heart Fail. 2017;4(1):40-45. 61. Bredemeier M, Lopes LM, Eisenreich MA, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018;18(1):24. 62. Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015;128(6):653 e657-653 e616. 63. Larsen KS, Pottegard A, Lindegaard HM, Hallas J. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. Am J Med. 2016;129(3):299-306 e292. 64. Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS One. 2014;9(6):e99102. 65. Zhang T, Pope JE. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology (Oxford). 2017;56(7):1144-1153. 66. White WB, Chohan S, Dabholkar A, Hunt B, Jackson R. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J. 2012;164(1):14-20. 67. MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014;4(7):e005354. 68. National Health Insurance Annual Report: 2016-2017. National Health Insurance Administration, Ministry of Health and Welfare, Executive Yuan; 2016. 69. Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25(7):1711-1719. 70. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11(2):R46. 71. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20(3):236-242. 72. Cheng C-L, Lee C-H, Chen P-S, Li Y-H, Lin S-J, Yang Y-HK. Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan. Journal of Epidemiology. 2014;24(6):500-507. 73. Harriss LR, Ajani AE, Hunt D, et al. Accuracy of national mortality codes in identifying adjudicated cardiovascular deaths. Aust N Z J Public Health. 2011;35(5):466-476. 74. Chen JH, Lan JL, Cheng CF, et al. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study. J Rheumatol. 2015;42(9):1694-1701. 75. Wu CS, Chang CM, Chen CY, et al. Association between antidepressants and venous thromboembolism in Taiwan. J Clin Psychopharmacol. 2013;33(1):31-37. 76. Lin TC, Lee CH, Yang CY, Yang YH, Lin SJ. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments. J Clin Endocrinol Metab. 2014;99(5):1599-1607. 77. Lee CH, Cheng CL, Kao Yang YH, Lin LJ. Hormone therapy and risk of venous thromboembolism among postmenopausal women in Taiwan - a 10-year nationwide population-based study. Circ J. 2015;79(5):1107-1114. 78. Mao YC, Chen ST, Chen CH, Hsieh KP, Gan KH. Rivaroxaban in preventing venous thromboembolism after arthroplastic surgery in Taiwan. Kaohsiung J Med Sci. 2015;31(10):534-539. 79. Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ. Association between migraine and risk of venous thromboembolism: A nationwide cohort study. Headache. 2016;56(8):1290-1299. 80. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19-25. 81. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43(5):480-485. 82. Saczynski JS, Andrade SE, Harrold LR, et al. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:129-140. 83. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:141-147. 84. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. 85. ATC/DDD Index 2018. WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health. https://www.whocc.no/atc_ddd_index/. Accessed Apr. 25, 2018. 86. 健保用藥品項. 衛生福利部中央健康保險署. https://www.nhi.gov.tw/Content_List.aspx?n=238507DCFE832EAE&topn=3FC7D09599D25979. Accessed Apr. 25, 2018. 87. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424. 88. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research. Communications in Statistics - Simulation and Computation. 2009;38(6):1228-1234. 89. Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33(6):1057-1069. 90. Deb S, Austin PC, Tu JV, et al. A Review of Propensity-Score Methods and Their Use in Cardiovascular Research. Can J Cardiol. 2016;32(2):259-265. 91. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150-161. 92. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users' guide to the medical literature. JAMA. 2014;311(4):405-411. 93. Ferreira JC, Patino CM. Subgroup analysis and interaction tests: why they are important and how to avoid common mistakes. J Bras Pneumol. 2017;43(3):162. 94. Xu X, Hu X, Lu Z, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail. 2008;14(9):746-753. 95. Hwang SJ, Lee KH, Jang HH, et al. Febuxostat contributes to improvement of endothelial dysfunction in an experimental model of streptozocin-induced diabetic rats. Int J Cardiol. 2014;171(3):e110-112. 96. Nomura J, Busso N, Ives A, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014;4:4554. 97. Shirakura T, Nomura J, Matsui C, Kobayashi T, Tamura M, Masuzaki H. Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(8):831-838. 98. Yu KH, Lai JH, Hsu PN, Chen DY, Chen CJ, Lin HY. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Scand J Rheumatol. 2016;45(4):304-311. 99. Essex MN, Hopps M, Bienen EJ, Udall M, Mardekian J, Makinson GT. Evaluation of the Relationship Between Serum Uric Acid Levels and Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using Electronic Medical Record Data. J Clin Rheumatol. 2017;23(3):160-166. 100. Zhang M, Solomon DH, Desai RJ, et al. Assessment of Cardiovascular Risk in Older Patients with Gout Initiating Febuxostat versus Allopurinol: A Population-Based Cohort Study. Circulation. 2018. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76416 | - |
dc.description.abstract | 目的:
Febuxostat和allopurinol為痛風及高尿酸血症的首選藥品治療,在藥理學分類上皆屬xanthine oxidase inhibitors (XOIs)。然而,美國Food and Drug Administration (FDA)不良事件通報系統的研究顯示febuxostat有潛在較高心血管栓塞不良事件的訊號,而在臨床試驗中也發現病人使用febuxostat相較於使用allopurinol後有顯著較高的心血管死亡和全死因死亡風險。本研究之目的係探討febuxostat使用者相較於allopurinol使用者是否增加心血管相關事件和死亡的風險,同時亦分析心血管不良事件是否和febuxostat的藥品使用劑量間存在劑量反應效果。 方法: 本研究為一回溯性世代研究,以臺灣全民健康保險資料庫為研究材料。研究納入於2012年4月1日至2015年12月31日間首次處方XOIs的病人,並分為febuxostat使用者和allopurinol使用者兩組,為平衡兩組病人之基礎特性,以傾向分數、指標日期 (index date)、有無腎功能不全病史和有無使用benzbromarone作為配對條件進行1:1配對。研究終點為主要心血管事件 (包含心肌梗塞、缺血性中風和心血管相關死亡)、靜脈栓塞、心血管疾病相關住院、心血管相關死亡和全死因死亡,使用Cox比例風險模式 (Cox proportional hazards models) 進行統計分析,估計兩組病人發生研究終點之風險比 (hazard ratios,HRs) 和95%信賴區間 (confidence intervals,CIs)。本研究亦將XOIs使用者之每日平均劑量以定義每日劑量 (defined daily dose,DDD) 表示,分為低劑量 (≤0.5 DDD)、中劑量 (>0.5 DDD, ≤1 DDD) 和高劑量 (>1 DDD) 3個類別,並以此作為模型中隨時間變化的變數,分析使用中、高劑量febuxostat相對於低劑量febuxostat發生研究終點事件的HRs和95% CIs。 結果: 在配對後兩組各包含44,111位病人,所有共變數在兩組間均平衡。在根據治療 (as-treated) 分析方法中,febuxostat使用者相較於allopurinol使用者有顯著較高的心衰竭住院 (HR=1.22;95% CI:1.13-1.33;兩組事件發生率分別為每1000人年60.1和51.0)、心房顫動住院 (HR=1.19;95% CI:1.05-1.36;兩組事件發生率分別為每1000人年23.7和20.7) 及心血管相關死亡 (HR=1.19;95% CI:1.03-1.36;兩組事件發生率分別為每1000人年19.2和17.2) 發生風險,而在主要心血管事件、靜脈栓塞、心肌梗塞住院、缺血性中風住院及全死因死亡無顯著相關。其中,多項敏感性分析結果均支持febuxostat的使用增加心衰竭住院風險這項研究結果。本研究之研究對象接受febuxostat或allopurinol的平均日劑量分別為53.1 mg (0.66 DDD) 和133.3 mg (0.33 DDD),劑量反應分析結果發現使用中、高劑量的febuxostat相較於使用低劑量的febuxostat,病人發生心血管事件的風險呈階梯式的增高。 結論: Febuxostat使用者相較於allopurinol使用者有顯著較高的心衰竭住院、心房顫動住院及心血管相關死亡發生風險,尤以增加心衰竭住院風險之結果更具穩健性;此外,febuxostat的使用劑量和心血管事件風險具劑量反應效果。我們建議臨床決策者在處方febuxostat時應追蹤心血管相關症狀和檢驗數值,未來需進一步的研究以了解febuxostat增加心血管事件風險之機轉。 | zh_TW |
dc.description.abstract | Objective:
Febuxostat and allopurinol are both xanthine oxidase inhibitors (XOIs) and recommended as the first-line pharmacological therapy for patients with hyperuricemia or gout. However, the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System indicated potential signals of febuxostat-associated cardiovascular (CV) thromboembolic events, and one clinical trial suggested a higher rate of all-cause and CV mortality with febuxostat than with allopurinol. This study aimed to assess whether febuxostat, compared to allopurinol, is associated with a higher risk of mortality and CV events. Also, the dose-response effects of febuxostat on the CV outcomes were analyzed. Methods: We conducted a retrospective cohort study using the National Health Insurance Research Database (NHIRD) in Taiwan. We identified patients who were first prescribed XOIs between 2012/4/1 and 2015/12/31 and classified them into groups of febuxostat users and allopurinol users. The two groups were 1:1 matched by the propensity score (PS), index date, history of renal impairment and benzbromarone use to balance the patient characteristics. Outcomes of interest were major adverse cardiovascular event (MACE, including myocardial infarction, ischemic stroke, and CV death), venous thromboembolism (VTE), CV-related hospitalization, CV death, and all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of the outcomes. In addition, to study the dose-response relationship, mean daily dose of XOIs users were estimated, categorized into low dose (≤0.5 defined daily dose, DDD), medium dose (>0.5 DDD, ≤1 DDD), and high dose (>1 DDD), and included as time-dependent variables in the Cox models. Results: We included 44,111 patients in each group after matching, and all the covariates were balanced between the two groups. In the as-treated analyses, febuxostat, compared with allopurinol, was associated with a significantly higher risk of heart failure (HR, 1.22; 95% CI, 1.13 to 1.33; incidence, 60.1 vs. 51.0/1000 person-years), atrial fibrillation (HR, 1.19; 95% CI, 1.05 to 1.36; incidence, 23.7 vs. 20.7/1000 person-years), and CV death (HR, 1.19; 95% CI, 1.03 to 1.36; incidence, 19.2 vs. 17.2/1000 person-years). However, a similar risk was found in MACE composite endpoint, VTE, myocardial infarction, ischemic stroke, and all-cause mortality. The elevated risk of heart failure was consistent throughout the main analysis and sensitivity analyses. The mean daily dose of febuxostat users and allopurinol users were 53.1 mg (0.66 DDD) and 133.3 mg (0.33 DDD), respectively. The use of medium- and high-dose febuxostat, compared with low-dose febuxostat, showed a hierarchically increased risk of CV outcomes. Conclusions: In the real-world setting, the use of febuxostat, compared with allopurinol, was associated with an increased risk of heart failure, atrial fibrillation, and CV death. The elevated risk of heart failure was found to be robust throughout the analyses. In addition, higher dose of febuxostat may result in a higher rate of CV outcomes. We recommend that health care professionals should carefully access CV-related symptoms and lab data in their patients when prescribing febuxostat. Further studies are needed to investigate the underlying mechanism of the CV adverse outcomes. | en |
dc.description.provenance | Made available in DSpace on 2021-07-09T15:52:02Z (GMT). No. of bitstreams: 1 ntu-107-R05451009-1.pdf: 5324198 bytes, checksum: 980c442a3ca0d64f2f6a394d9e7a23c8 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii 英文摘要 iv 目錄 vii 圖目錄 x 表目錄 xi 縮寫表 xii 第一章 前言 1 第二章 文獻探討 2 第一節 痛風與高尿酸血症的流行病學 2 第二節 痛風的臨床病程分期及診斷 4 第三節 痛風與高尿酸血症和心血管疾病風險的關係 6 2.3.1 血尿酸濃度和心血管疾病風險 6 2.3.2 血尿酸濃度和研究終點的U型相關 9 第四節 降尿酸藥品的使用時機和選擇 11 第五節 XOI的特性與使用建議 14 2.5.1 Allopurinol和Febuxostat的藥理、藥化與藥動特性 14 2.5.2 Allopurinol和Febuxostat的上市時間和給付規定 15 2.5.3 Allopurinol和Febuxostat的常用劑量及劑量調整建議 16 2.5.4 Allopurinol和Febuxostat的常見副作用 17 第六節 XOI的使用和心血管疾病風險之文獻回顧 18 第七節 Febuxostat對於心血管疾病風險的疑慮 21 2.7.1 Febuxostat短期臨床試驗中心血管相關事件的發現 22 2.7.2 Febuxostat長期臨床試驗中心血管相關事件的發現 24 2.7.3 Febuxostat以心血管安全性為研究終點的臨床試驗 25 2.7.4 Febuxostat相關心血管栓塞不良事件的通報情形 27 第三章 研究目的 28 第四章 研究方法 29 第一節 研究材料 29 第二節 研究設計 30 第三節 研究族群與各項定義 31 4.3.1 研究族群的納入與排除條件 31 4.3.2 追蹤期間定義 33 4.3.3 研究終點定義 35 4.3.4 研究分組及配對 38 4.3.5 背景資料分析與共變數定義 38 第四節 統計分析 41 4.4.1 描述性統計分析 41 4.4.2 傾向分數配對 42 4.4.3 研究終點統計分析 42 第五節 敏感性分析及次族群分析 43 第六節 劑量與效果相關性分析 44 第五章 研究結果 45 第一節 研究族群與背景資料分析 45 5.1.1 研究族群納入與分組 45 5.1.2配對前族群背景資料分析 45 5.1.3 傾向分數的建立與配對結果 45 5.1.4配對後族群背景資料分析 46 第二節 主要研究結果 47 第三節 敏感性分析結果 48 第四節 次族群分析結果 50 第五節 劑量與效果相關性分析結果 51 第六章 討論 53 第一節 研究族群與背景資料 53 第二節 XOI的使用與心血管安全性 54 6.2.1 XOI的使用與主要心血管事件 54 6.2.2 XOI的使用與靜脈栓塞 55 6.2.3 XOI的使用與心血管相關住院 56 6.2.4 XOI的使用與心血管相關死亡和全死因死亡 57 第三節 Febuxostat增加心血管風險之可能原因 59 第四節 本研究之優點與限制 62 6.4.1 研究優點與特色 62 6.4.2 研究限制 63 第五節 結論與建議 64 Figures 65 Tables 76 參考文獻 94 | |
dc.language.iso | zh-TW | |
dc.title | Febuxostat和Allopurinol之心血管安全性比較:以傾向分數配對之世代研究 | zh_TW |
dc.title | Comparative Cardiovascular Safety of Febuxostat and Allopurinol: A Propensity Score-Matched Cohort Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 林芳如 | |
dc.contributor.oralexamcommittee | 謝松洲,林亮宇 | |
dc.subject.keyword | Febuxostat,allopurinol,黃嘌呤氧化?抑製劑 (xanthine oxidase inhibitors,XOIs),心血管安全性,藥品不良反應, | zh_TW |
dc.subject.keyword | Febuxostat,allopurinol,xanthine oxidase inhibitors,cardiovascular safety,adverse drug reaction, | en |
dc.relation.page | 100 | |
dc.identifier.doi | 10.6342/NTU201802468 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2018-08-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
dc.date.embargo-lift | 2023-10-05 | - |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-R05451009-1.pdf | 5.2 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。